What do we actually know about the relationship between arterial hypertension and atrial fibrillation?

References

• Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Blackshear JL, Shen W-K, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol. 2001;37:371–378.
   PubMed Web of Science ®Google Scholar
• Zateyshchikov DA, Brovkin AN, Chistiakov DA, Nosikov VV. Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2010;30:192–199.
   Google Scholar
• Russell D. Atrial fibrillation and stroke. Cerebrovasc Dis. 2012;33:23.
   Google Scholar
• Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22:11–19.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–2434.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol. 1998; 82 Suppl:2N–9N.
   Google Scholar
• Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Kjeldsen SE, Arnesen H, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: A 35-year follow-up study. Hypertension. 2012;59:198–204.
   PubMed Web of Science ®Google Scholar
• Rosiak M, Dziuba M, Chudzik M, Cygankiewicz I, Bartczak K, Drozdz J, et al. Risk factors for atrial fibrillation: Not always severe heart disease, not always so “lonely”. Cardiol J. 2010;17:437–442.
   Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.JAMA. 1994; 271:840–844.
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz M. Diastolic dysfunction and atrial fibrillation. J Interv Card Electrophysiol. 2008;22:111–118.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, Sakadakis EA, Triantafyllis A, Kremastinos DT, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;11:77–83.
   Google Scholar
• Go O, Rosendorff C. Hypertension and atrial fibrillation. Curr Cardiol Rep. 2009;11:430–435.
   PubMedGoogle Scholar
• Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, et al. Hypertension and atrial fibrillation: Diagnostic approach, prevention and treatment. Position paper of the Working Group “Hypertension Arrhythmias and Thrombosis” of the European Society of Hypertension. J Hypertens. 2012;30:239–252.
   PubMed Web of Science ®Google Scholar
• Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: Mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33:1870–1877.
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: A rationale for early restoration and maintenance of sinus rhythm. Europace. 2006;8:943–949.
   Google Scholar
• Byrd GD, Prasad SM, Ripplinger CM, Cassilly TR, Schuessler RB, Boineau JP, et al. Importance of geometry and refractory period in sustaining atrial fibrillation. Testing the Critical Mass Hypothesis. Circulation. 2005;112 Suppl 1:I7–I13.
   Google Scholar
• Parati G, Esler M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–1066.
   PubMed Web of Science ®Google Scholar
• Lu Z, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L, et al. Atrial fibrillation begets atrial fibrillation: Autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. Circ Arrhythm Electrophysiol. 2008;1:184–192.
   PubMedGoogle Scholar
• Dimmer C, Tavernier R, Gjorgov N, Van Nooten G, Clement DL, Jordaens L. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1998;82:22–25.
   PubMed Web of Science ®Google Scholar
• Coccagna G, Capucci A, Bauleo S, Boriani G, Santarelli A. Paroxysmal atrial fibrillation in sleep. Sleep. 1997;20: 396–398.
   PubMed Web of Science ®Google Scholar
• Herweg B, Dalal P, Nagy B, Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 1998; 82:869–874.
   PubMed Web of Science ®Google Scholar
• Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005;2:624–631.
   PubMed Web of Science ®Google Scholar
• Choi EK, Shen MJ, Han S, Hwang S, Sayfo S, Piccirillo G, et al. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation. 2010; 121: 2615–2623.
   PubMed Web of Science ®Google Scholar
• Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35: 1669–1677.
   PubMed Web of Science ®Google Scholar
• McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998; 98:2765–2773.
   PubMed Web of Science ®Google Scholar
• Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-Ras and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol. 2003; 284:176–184.
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006;15:532–537.
   Google Scholar
• Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: Clinical and experimental evidence. Eur Heart J. 2006;27:512–518.
   PubMed Web of Science ®Google Scholar
• Grassi G. Renin–angiotensin–sympathetic crosstalks in hypertension: Reappraising the relevance of peripheral interactions. J Hypertens. 2001;19:1713–1716.
   PubMedGoogle Scholar
• Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709–715.
   PubMed Web of Science ®Google Scholar
• Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, et al. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012;60:347–353.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. ONTARGET-TRANSCEND study. J Hypertens. 2012;30:1004–1014.
   PubMed Web of Science ®Google Scholar
• Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146–2152.
   PubMed Web of Science ®Google Scholar
• Hurley V, Ireson R, Fletcher K, Lip GY, Hobbs FD, Mant J; BAFTA Investigators. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: Secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. Int J Cardiol. 2007;117:152–156.
   PubMed Web of Science ®Google Scholar
• Thacker EL, McKnight B, Psaty BM, Longstreth WT Jr, Dublin S, Jensen PN, et al. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. J Gen Intern Med. 2013;28: 247–253.
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Lapenna D, Cuccurullo F. Risk of atrial fibrillation in dipper and nondipper sustained hypertensive patients. Blood Press Monit 2008;13:193–197.
   PubMed Web of Science ®Google Scholar
• Webb AJ, Rothwell PM. Blood pressure variability and risk of new-onset atrial fibrillation: A systematic review of randomized trials of antihypertensive drugs. Stroke. 2010; 41:2091–2093.
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–1756.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616.
   PubMed Web of Science ®Google Scholar
• L’Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004; 44:159–164.
   Google Scholar
• Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712–719.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens. 2008;26:403–411.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–1237.
   PubMed Web of Science ®Google Scholar
• , ONTARGET InvestigatorsYusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547–1559.
   PubMed Web of Science ®Google Scholar
• , GISSI-AF InvestigatorsDisertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, et al. Valsartan for prevention of recurrent atria fibrillation. N Engl J Med. 2009;360: 1606–1617.
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21:1034–1039.
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47:46–50.
   PubMed Web of Science ®Google Scholar
• Galzerano D, Caselli, S, Breglio R. A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation. 2007;116 Suppl II:556–557.
   Google Scholar
• Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG. Systematic review and meta-analysis: Renin–angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: An unfulfilled hope. Cardiovasc Drugs Ther. 2012;26:47–54.
   Google Scholar
• Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: A meta-analysis. Eur J Clin Invest. 2011;41:719–733.
   PubMed Web of Science ®Google Scholar
• Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: A review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1222–1228.
   Google Scholar
• Wachtell K, Devereux RB, Lyle PA. Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Curr Cardiol Rep. 2006;8:356–364.
   Google Scholar
• Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A metaanalysis. J Am Coll Cardiol. 2005; 45:1832–1839.
   PubMed Web of Science ®Google Scholar
• Kalus JS, Coleman CI, White CM. The impact of suppressing the renin–angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46:21–28.
   Web of Science ®Google Scholar
• Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin–angiotensin system-inhibition a meta-analysis. J Am Coll Cardiol. 2010; 55:2299–2307.
   PubMed Web of Science ®Google Scholar
• Bhuriya R, Singh M, Sethi A, Molnar J, Bahekar A, Singh PP, et al. Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: A systematic review and meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther. 2011;16: 178–184.
   Google Scholar
• Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, et al. The role of renin–angiotensin system blockade therapy in the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010; 88:521–531.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (esh) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010;19:169–175.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343–2349.
   PubMed Web of Science ®Google Scholar
• Werner C, Pöss J, Böhm M. Optimal antagonism of the renin–angiotensin–aldosterone system: Do we need dual or triple therapy?Drugs. 2010;70:1215–1230.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364: 11–21.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;11:530–537.
   Google Scholar
• Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J. 2007;28:457–462.
   PubMed Web of Science ®Google Scholar
• Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med. 2010;152:78–84.
   PubMed Web of Science ®Google Scholar
• De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 1999;34: 810–814.
   Google Scholar
• Lee SH, Yu WC, Cheng JJ, Hung CR, Ding YA, Chang MS, Chen SA. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000; 101:200–206.
   PubMed Web of Science ®Google Scholar
• Bandeali SJ, Kayani WT, Lee VV, Elayda M, Alam M, Huang HD, et al. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Mar 20. doi: 10.1111/1755–5922.12024. [Epub ahead of print].
   Google Scholar
• Chelazzi C, Villa G, De Gaudio AR. Postoperative atrial fibrillation. ISRN Cardiol. 2011;2011:203179.
   Google Scholar
• Edwards JD, Wilkins RG. Atrial fibrillation precipitated by acute hypovolaemia. Br Med J (Clin Res Ed). 1987;294: 283–284.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: Comparison of six antihypertensive agents. Circulation. 1998;98: 140–148.
   PubMedGoogle Scholar
• Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95: 2007–2014.
   Google Scholar
• Conti A, Canuti E, Mariannini Y, Zanobetti M, Innocenti F, Paladini B, et al. Aggressive approach and outcome in patients presenting atrial fibrillation and hypertension. Int J Cardiol. 2011 Oct 8. [Epub ahead of print].
   Google Scholar